The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site

描述(由申请人提供)：太平洋癌症研究联盟(PCRC)将美国西部的社区癌症治疗中心聚集在一起，形成了一个NCI社区肿瘤研究计划(NCORP)社区网站。PCRC包括西雅图的瑞典癌症研究所及其前U10附属机构(Puget Sound Oncology Consortium)、波特兰的普罗维登斯·波特兰医疗中心及其前社区临床肿瘤计划附属机构(Western Oncology Research Consortium)和博伊西的山州肿瘤研究所。在多重PI/PD结构下，PCRC的3个主要组成部分将定义和促进华盛顿、俄勒冈、爱达荷州、阿拉斯加和加利福尼亚州的24个参与组成部分和14个子组成部分的临床试验和癌症护理提供研究议程。我们的每个主要组成部分都拥有数十年进行癌症临床试验的经验，并计划参与研究设计的方方面面，进行NCI批准的临床研究和癌症护理交付研究，尤其注重促进少数族裔和服务不足的人群参与我们集水区内所有研究类型和环境，在参与机构和我们的研究基地内提供生物标本库和分享实践，并将基因组医学和靶向治疗纳入我们的研究能力组合。我们还计划建造 为癌症护理提供研究提供多中心基础设施和研究议程，以支持NCTN提出的试验，使我们能够参与CC DR研究的新方法的开发。

DESCRIPTION (provided by applicant): The Pacific Cancer Research Consortium (PCRC) brings together community cancer treatment centers in the Western United States to form an NCI Community Oncology Research Program (NCORP) Community Site. The PCRC includes Swedish Cancer Institute in Seattle and its former U10 affiliates (the Puget Sound Oncology Consortium), Providence Portland Medical Center in Portland and its former Community Clinical Oncology Program affiliates (the Western Oncology Research Consortium), and Mountain States Tumor Institute in Boise. Under a multiple PI/PD structure, the 3 primary components of the PCRC will define and facilitate the clinical trial and cancer care delivery research agenda across 24 participating components and 14 sub-components in Washington, Oregon, Idaho, Alaska, and California. Each of our primary component sites has decades of experience conducting clinical trials in cancer and plan to participate in all aspect of study design and conduct NCI-approved clinical studies and cancer care delivery research, with particular focus on facilitating the participation of minorities and underserved populations across all study types and settings within our catchment areas, providing bio specimen banking and sharing practices within the participating institutions and with our research bases, and incorporating genomic medicine and targeted therapies into our portfolio of research capabilities. We also plan to build a multicenter infrastructure and research agenda for cancer care delivery research to support the trials proposed by the NCTN, allowing us to participate in the development of novel approaches to CC DR studies.